Proton Beam Therapy - the Challenges of Delivering High-quality Evidence of Clinical Benefit.
Date
2018-05-01ICR Author
Author
National Cancer Research Institute Clinical and Translational Radiotherapy Research Working Group (CTRad) Proton Beam Clinical Trial Strategy Group,
Type
Journal Article
Metadata
Show full item recordAbstract
The use of proton beam therapy (PBT) offers the opportunity to improve greater conformality of radiotherapy treatment delivery in some patients. However, it is associated with a high capital cost and the need to build new dedicated facilities. We discuss how the global radiotherapy community can respond to the challenge of producing high-quality evidence of clinical benefit from PBT in adult patients. In the UK, the National Cancer Research Institute-funded Clinical and Radiotherapy Translational group has established the PBT Clinical Trial Strategy Group. An eight-point framework is described that can assist the development and delivery of high-quality clinical trials.
Collections
Subject
National Cancer Research Institute Clinical and Translational Radiotherapy Research Working Group (CTRad) Proton Beam Clinical Trial Strategy Group
Humans
Neoplasms
Research Design
Adult
Clinical Trials as Topic
Proton Therapy
United Kingdom
Research team
ICR-CTSU Urology and Head and Neck Trials Team
Language
eng
Date accepted
2018-02-19
License start date
2018-05
Citation
Clinical oncology (Royal College of Radiologists (Great Britain)), 2018, 30 (5), pp. 280 - 284
Publisher
ELSEVIER SCIENCE LONDON
Related items
Showing items related by title, author, creator and subject.
-
Ethical Considerations for the Inclusion of Patient-Reported Outcomes in Clinical Research: The PRO Ethics Guidelines.
Cruz Rivera, S; Aiyegbusi, OL; Ives, J; Draper, H; Mercieca-Bebber, R; et al. (AMER MEDICAL ASSOC, 2022-05-17)IMPORTANCE: Patient-reported outcomes (PROs) can inform health care decisions, regulatory decisions, and health care policy. They also can be used for audit/benchmarking and monitoring symptoms to provide timely care ... -
The UK plasma based molecular profiling of advanced breast cancer to inform therapeutic choices (plasmamatch) trial: a multiple parallel cohort, open-label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening (CRUK/15/010)
Bliss, J; Kernaghan, S; Fribbens, C; Stevenson, L; Morden, J; et al. (BIOMED CENTRAL LTD, 2017-05-08) -
Training and accreditation standards for pathologists undertaking clinical trial work.
Rees, G; Salto-Tellez, M; Lee, JL; Oien, K; Verrill, C; et al. (WILEY, 2019-04-01)Clinical trials rely on multidisciplinary teams for successful delivery. Pathologists should be involved in clinical trial design from the outset to ensure that protocols are optimised to deliver maximum data collection ...